Chi Fung Lee

Oklahoma Medical Research Foundation

$2,929,670

Attributed

$2,929,670

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1M · FY2021–25

$2M$1.5M$1M$500K$0

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$2,929,670 · 2

By mechanism

R01$1,854,721 · 1

P20$1,074,949 · 1

Top collaborators

No co-investigators on record.

Most similar at Oklahoma Medical Research Foundation

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Pathway Interactions”

April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
Kevin Urdahl · Seattle Children'S Hospital$47,227,116
Urs Ochsner · Crestone, Inc.$38,569,476
Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
Jeffrey Glenn · Stanford University$26,017,226

Research focus

Pathway InteractionsConsumptionHeart FunctionPathogenicityStressCardiacFunctional DisorderHeart FailureMediatingNew Therapeutic TargetPhosphorylationProteinsCardiac MyocytesTranscriptDiabeticDiabetic CardiomyopathyCause Of DeathHeartHomeostasisLinkMitochondriaCardiomyopathiesAxon InjuryCardiac Health

Grant awards (6)

Roles of SARM1 NAD hydrolase in metabolic cardiomyopathy$616,475

R01 · FY2025 · HL · contact PI

Roles of SARM1 NAD hydrolase in metabolic cardiomyopathy$604,146

R01 · FY2024 · HL · contact PI

Roles of SARM1 NAD hydrolase in metabolic cardiomyopathy$634,100

R01 · FY2023 · HL · contact PI

Roles of NAD+ metabolism in diabetic cardiomyopathy$375,749

P20 · FY2023 · GM · contact PI

Roles of NAD+ metabolism in diabetic cardiomyopathy$349,600

P20 · FY2022 · GM · contact PI

Roles of NAD+ metabolism in diabetic cardiomyopathy$349,600

P20 · FY2021 · GM · contact PI